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Available online 8 March 2018Dilated Cardiomyopathy (DCM) has been classically considered a progressive disease of the heart muscle that in-
exorably progresses towards refractory heart failure, ventricular arrhythmias and heart transplant. However, the
prognosis of DCM has signiﬁcantly improved in the past few years, mostly as the result of successful therapy-
induced reverse remodeling. Reverse remodeling is a complex process that involves not only the left ventricle,
but also many other cardiac structures and it is now recognized both as a measure of therapeutic effectiveness
and as an important prognostic tool. Nevertheless, several aspects of reverse remodeling remain unclear,
including the best timing for its quantiﬁcation, its predictors and its interaction with individual genetic
backgrounds. In this review, we summarize our current understanding of reverse remodeling in patients with
DCM and provide practical recommendations for the clinical management of this challenging patient population., Azienda
34100 T
).
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Dilated Cardiomyopathy (DCM) is a disease of the heart muscle
characterized by left ventricular (LV) or biventricular dilation and
systolic dysfunction in the absence of pressure overload or coronary
artery disease sufﬁcient to explain the observedmyocardial dysfunction
[1,2]. The estimated incidence and prevalence of DCM are 7 cases per
100.000 people/year and 1 in 2500 respectively in western populations,
but there are marked race-related differences and geographical differ-
ences. The prevalence of DCM in Africa and Latin America has been
shown to be double that of western populations, while the prevalence
of the disease in Japan is about half of the one above reported [3].
DCM is regarded not as a single disease entity, but rather a nonspeciﬁc
ﬁnal common response to a number of genetic and environmental in-
sults [4]. DCM etiologies can be classiﬁed as genetic or non-genetic [1].
Genetic causes account for 30–40% of DCMs and involve genes that
encode cytoskeletal, sarcomere and nuclear envelope proteins among
others. Transmission is variable butmostlywith anautosomal dominant
pattern [5]. Acquired causes include myocarditis, tachyarrhythmias,
alcohol abuse, drugs, catecholamines, toxins, and metabolic or endo-
crine disturbances [3].
In the past, the prognosis of DCM was considered ominous [6].
During the last decades, the 10 year survival free from heart transplan-
tation has improved impressively and currently it is close to 85% [7].Sanitaria Universitaria
rieste, Italy.
an open access article underNevertheless, the outcome of patients with DCM often remains unpre-
dictable and major adverse events may occur in the ﬁrst months fol-
lowing the diagnosis [2,8]. The societal and economic impact of these
adverse events is ampliﬁed by the fact that DCM often affects patients
in the ﬁrst decades of life.
The most important determinants of the improvement in the prog-
nosis of DCM observed over the past few years are: 1) the implementa-
tion of systematic familial screening programs for DCM that have
enabled earlier diagnosis with long-term individualized follow-up;
2) the systematic implementation of evidence based medical and
device therapies that promote Left Ventricular Reverse Remodeling
(LVRR), deﬁned as an improvement in Left Ventricular Ejection Fraction
(LVEF), and a reduction in left ventricular dimension. Therapy-induced
reverse remodeling has been recently recognized as an important prog-
nostic tool [9,10] in the management of patients with DCM. Several re-
cent reports have suggested that reverse remodeling might be a global
myocardial process involving not only left ventricle contractile function,
but also mitral regurgitation, left ventricular diastolic function and the
right ventricle [11–13]. Here we review our current knowledge of
reverse remodeling in DCM patients, highlighting persistent gaps of
knowledge, and providing practical recommendations for the clinical
management of DCM.
2. Left Ventricular Reverse Remodeling
Cardiac remodeling in response to an inciting myocardial insult or
an underlying genetic abnormality has been classically considered the
hallmark of DCM. It can be deﬁned as the result of molecular, cellular,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ations in the size, shape, and function of the cardiac muscle [14,15]. In
the last decade, several cohort studies have shown that a signiﬁcant por-
tion of patients with DCM (i.e. about 40%) can experience a reversal of
this phenomenon, in a process generally referred to as reverse remodel-
ing, speciﬁcally referring to LV (i.e. LVRR) (Table 1). Theseﬁndings imply
that DCM does not represent an irreversible progressive pathway of
myocardial failure but it is rather a dynamic diseasewith non-linear pro-
gression [9,16]. Reverse remodeling can take place spontaneously upon
removal of the inciting cardiac insult (for instance in tachycardia-
induced cardiomyopathy or toxin-induced cardiomyopathy) but it is
more often the result of evidence-based pharmacological and non-
pharmacological therapies [17,18]. The classical medical management
of DCM is based on treatment with ACE-inhibitors/angiotensin receptor
blockers, beta-blockers andmineralocorticoid receptor antagonists [19].
In patients with Left Bundle Branch Block (LBBB) and possible conse-
quent ventricular dyssynchrony, Cardiac Resynchronization Therapy
(CRT) can successfully induce LVRR [17,18]. Notably, when comparing
patients with ischemic and non-ischemic cardiomyopathy, non-
ischemic etiology of heart failure (HF) seems to be a predictor of
positive response to CRT. LVRR has also been observed in response to
ventricular unloading with Left Ventricular Assist Devices (LVAD) [20].
In a sizeable portion of patients (up to 15%), LVRR was pronounced
enough to result in a normalization of both LVEF and LV diameters, in
a process that has been referred to as “apparent healing” or “myocardial
remission” [20]. Interestingly, only about 10% of DCM patients showed
persistent apparent healing at long term (N10 years) [21] and the
vast majority of them experienced a recurrence of left ventricular
dysfunction in the very long term, showing that the observed healing
was only apparent and that true myocardial recovery is at most a rare
event in DCM patients [21,22]. The mechanistic basis of apparent
healing remains largely unknown. Recent work in animal models sug-
gests that it might be secondary to an incomplete reversal of the gene
expression changes characteristic of cardiac dysfunction [23], but data
in humans are scarce, as is our understanding of the complex interplay
that individual genetic backgrounds and environmental factors play in
this process.
2.1. LVRR: a mechanistic view
From a pure mechanistic standpoint, LVRR is the result of either the
removal of the noxious stimuli that triggered cardiac dysfunction or of
the institution of therapies that interfere with the process of LV remod-
eling. Factors recognized to trigger or amplify LV remodeling include
changes in myocardial wall tension and neurohormonal activation.Table 1
Main studies evaluating LVRR in DCM patients.
Study N° of pts Assessment of Left
Merlo M et al. J Am Coll Cardiol 2011 242 LVEF increase ≥10%
reduction ≥10% or t
Amorim S et al. Rev Port Cardiol 2016 113 LVEF increase N10%
(not speciﬁed) in a
Matsumura Y et al. Am J Cardiol 2013 19 LVEDD decreased to
improved to ≥25%
Kubanek M et al. J Am Coll Cardiol 2013 44 LVEF increase ≥10%
LVEDD ≥10%
McNamara DM et al. J Am Coll
Cardiol 2011
373 (DCM +myocarditis) 1. LVEF increase ≥1
2. LVEF increase ≥2
Hoshikawa E et al. Am J Cardiol 2011 33 LVEDD decreased to
improved to ≥25%
Ikeda Y et al. Heart vessels 2015 207 LVEF increased to N
iLVEDD ≥10%
Masci PG et al. Circ Card Imag 2013 58 LVEF increased ≥10
≥10% as assessed by
LVRR: Left Ventricular Reverse Remodeling; LVEF: Left Ventricular Ejection Fraction; LVEDD: Lef
Cardiac Resynchronization Therapy; DCM: Dilated Cardiomyopathy; iLVEDD: indexed Left VenAccording to Laplace's law, myocardial wall tension is mostly deter-
mined by LV diameter and LV wall thickness: LV dilation and wall thin-
ning increase LV wall tension and worsen myocardial energetics. An
increase in afterload, as observed in hypertension, can also increase
wall tension, and patients with a long standing history of hypertension
can develop LV dysfunction with a phenotype overlapping that of DCM
[24]. Neurohormonal activation has been clearly shown to play a critical
role in the pathophysiology of HF and DCM in several landmark studies.
Initially a compensatory process, the release of hypovolemic hormones
(such as renin, antidiuretic hormone and norepinephrine) eventually
contributes to the progression of DCM and pharmacologic therapies
that reduce neurohormonal activation have been shown to promote
LVRR.
2.1.1. Beta blockers
The beneﬁcial effects of beta blocker therapy in patients with HF
with reduced Ejection Fraction (HFrEF) are likely the result of a reduc-
tion of the detrimental effects of chronic catecholamine stimulation on
the kidneys (increased sodium retention) and the heart. The negative
effects of continued catecholamine stimulation on the heart include
elevated heart rate, increased myocardial energy demand, adverse re-
modeling due to cardiac myocyte hypertrophy and damage, interstitial
ﬁbrosis, impaired beta-adrenergic signaling and increased sodium re-
tention [25]. Beta blockade has been shown to have beneﬁcial effects
on LV gene expression, geometry and mass [26] and to consistently im-
prove LVEF in patients with HF [27]. Moreover, the improvement in LV
geometry associated with beta blockade can diminish functional mitral
regurgitation with subsequent improvement of LV shape and function
[28]. These beneﬁts require chronic therapy.
2.1.2. ACE inhibitors and angiotensin receptor blockers (ARBs)
In the context of HF, Angiotensin II has many renal and hemody-
namic effects similar to those of catecholamines, such as an increase
in sodium reabsorption and induction of systemic and renal vasocon-
striction. Angiotensin II can also act directly on cardiomyocytes, pro-
moting pathologic remodeling and inducing myocyte hypertrophy, re-
expression of fetal protein isoforms, myocyte apoptosis, and alterations
in the interstitial matrix. In light of this, the beneﬁcial effects of treat-
ment with ACE inhibitors and ARBs should not be entirely ascribed
to their effects of the kidneys and the vasculature but also keep into
account their direct effects on cardiomyocytes [29].
2.1.3. Mineralocorticoid receptor antagonists
In the pathophysiology of HFrEF, mineralocorticoid excess promotes
sodium retention, electrolyte imbalance and endothelial dysfunctionVentricular Reverse Remodeling Time of LVRR Prevalence
LVRR
points or ≥50% and LVEDD
o ≤33 mm/m2
24 months (follow-up 10 years) 37%
points and decrease LVEDD
bsence of CRT
24 months (follow-up 7 years) 35%
≤55 mm and fractional shortening 12 months (follow-up 10 years) 37%
points (N35%) and decrease in 12 months 45%
0% points 6 months (follow-up 48 months) 70%
0% points 39%
≤55 mm and fractional shortening 5 years 42%
10% points and decrease in b24 months 40%
≥24 months Further 12%
% points and decrease in LVEDV
cardiac magnetic resonance
24 months 38%
t Ventricular EndDiastolic Dimension; LVEDV: Left Ventricular EndDiastolic Volume; CRT:
tricular End Diastolic Dimension.
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alocorticoid receptor antagonists have been shown to reduce mortality,
hospitalizations and sudden deaths if used on top of ACE inhibitors and
beta blockers [30].
Secondary hyperaldosteronism in HF has been thought to reﬂect
Angiotensin II-mediated stimulation of the adrenal glands. However,
there is also evidence of local production of aldosterone in the failing
heart in proportion to the severity of HF [31]. This has been linked to
the induction of aldosterone synthase (CYP11B2) by Angiotensin II in
the failing ventricle [32]. Blockade of the adverse effects of aldosterone-
induced stimulation of cardiac mineralocorticoid receptors is thought
to contribute to the survival beneﬁt associated with the administration
of this class of drugs in HF with reduced ejection fraction [30].
2.1.4. Cardiac Resynchronization Therapy (CRT)
LBBB is common in DCM and it is mechanically disadvantageous be-
cause it results in intraventricular dyssynchrony of the septum (when
compared to the lateral or posteriorwalls) and paradoxical septalmotion.
Abnormal contraction patterns promote pathologic LV remodeling by in-
creasing LV volumes, reducing diastolic ﬁlling, and prolonging the dura-
tion of MR. In DCM, LBBB may be either causative or secondary to the
underliningdisease. LBBBmay in fact be the cause of non-ischemic cardio-
myopathy and in selected patients its resolution through CRThas been as-
sociated with normalization of LV function [33]. On the other hand, DCM
is associated with ventricular rearrangements and conduction delays, ul-
timately leading to LBBB [34]. Thus, CRT has become an established treat-
ment for selected patients with refractory symptomatic systolic HF [35].
Notably, the response to evidence-based therapies is variable, and
reverse remodeling is not evident in all cases. The reasons for this vari-
ability in therapeutic success are not completely known. However, they
are partially related to the variable etiology of DCM that encompasses
both non-genetic and genetic variants.
2.2. Non-genetic DCMs
A comprehensive integrated approach to patients with a newly diag-
nosed DCM is essential in order to achieve an accurate early prognostic
stratiﬁcation. After excluding common etiologies of reduced ejection
fraction such as ischemic heart disease, primitive valve disease, congen-
ital disorders and long-lasting hypertension, healthcare providers should
systematically undertake amore detailed etiological classiﬁcation. Every
possible reversible cause of cardiomyopathy should be excluded in clin-
ical practice to identify any needed therapeutic intervention speciﬁc to a
particular etiology. The most common forms of non-genetic DCM that
all providers should be aware of are listed below.
• Sustained supraventricular arrhythmias or very frequent ventricular
ectopic beats (tachycardiomyopathy): both sustained supraventricu-
lar arrhythmias and very frequent ventricular ectopic beats can
precipitate DCM. The mechanisms leading to left ventricular dysfunc-
tion are different depending on the type of underlining arrhythmia.
Sustained supraventricular arrhythmias promote cardiac dysfunction
through high ventricular rate and increased oxygen consumption.
Conversely, frequent ectopic ventricular beats are thought to deter-
mine dyssynchrony-induced ventricular dysfunction. In both type
of arrhythmias, treatment of the arrhythmia (i.e. maintenance of
sinus rhythm or control of ventricular rate) invariably results in im-
provement in cardiac function, often until complete normalization
[5]. The role of genetic background in tachyarrhythmia-induced car-
diomyopathy remains unclear and the early distinction between real
tachycardia-induced cardiomyopathy and DCM presenting with
high rate supraventricular arrhythmia or frequent ventricular ectopic
beats remains a clinical challenge.
• Substance abuse (e.g. alcohol, cocaine) can induce a form of cardio-
myopathy that is often reversible, at least to a certain extent, after in-
terruption of the causing agent.• Cardiotoxic agentsmostly related to anthracycline and trastuzumab
used in oncologic treatments can cause cardiac dysfunction that could
improve upon removal of the offending drug. Repeated exposure to
the offending drug often causes worsening cardiac function.
• Systemic autoimmune disease (e.g. Churg-Strauss syndrome and
sarcoidosis) can cause cardiac dysfunction that requires aggressive
immunosuppressive therapy.
• Peripartum cardiomyopathy, deﬁned as LV dysfunction that occurs
during the last trimester of pregnancy or the early puerperium,
frequently shows normalization of LV function after the delivery. How-
ever, this can be a state of myocardial remission that can deteriorate
rapidly with subsequent pregnancies and requires speciﬁc counseling
about future pregnancies
• Active myocarditis, mainly caused by poorly understood interactions
between viral infection and individual genetic background. It is treated
with standardHF therapy and, in selected cases,with immunosuppres-
sive therapy. It can resolve rapidlywith favorable outcome or evolve to
post-myocarditis DCM [36]. Patients with heart failure and severe sys-
tolic dysfunction carry the poorest diagnosis. In these patients, when
refractory to standard therapy, endomyocardial biopsy might be im-
portant to conﬁrm the clinical diagnosis and guide speciﬁc therapies.
2.3. The emerging role of genetics in predicting LVRR
The advent of high-quality next-generation sequencing (NGS)
extended panels has shown that DCM is genetically determined in a
much larger number of cases (i.e. up to 40–50%) than previously appre-
ciated. In the genetic landscape of DCM, mutations in the gene for Titin
are the most frequently encountered. Other genes involved encode
components of cardiac sarcomere, desmosome, cytoskeleton, nuclear
envelope, mitochondria and ion channels [37]. Genotype-phenotype
correlations in DCMare currently still scarce. However, the interplay be-
tween genetic background and response to therapy, as measured by
LVRR, is an upcoming frontier for investigators studying DCM. Recently,
a cohort study of 152 patientswith DCM found a signiﬁcant relationship
between gene cluster mutation type and probability of LVRR [38]. In
particular, a lower rate of LVRRwas found in patients carrying structural
cytoskeleton Z-diskgenemutations (Desmin [DES], Filamin C [FLNC] and
Distrophin [DMD],OBSL1,NEXN,MYPN,NEBL, LDB3) [38]. These ﬁndings
reinforce the importance of collecting a detailed family history and
planning familial screening as part of the initial assessment of DCM
patients. Moreover, they endorse the need for a detailed clinical and in-
strumental evaluation aimed at detecting clues of genetic determinants
of disease (i.e. the so called red-ﬂags:mental retardation, deafness,mus-
cle disorders, increased creatine-kinase or lactates, infero-posterior
pseudonecrosis or 1st degree atrio-ventricular block at ECG, aneurisms
at echocardiography or cardiac magnetic resonance) [39,40]. In fact,
the presence of familial forms or “red-ﬂags” on exam should trigger im-
mediate genetic testing [41]. In the future GWAS studies investigating
speciﬁc individual genetic predispositions associated with a favorable
response to therapy will be needed to improve the granularity of prog-
nostic evaluation of patients.
3. Beyond LV and LVRR: comprehensive reverse remodeling
LVRR is a dynamic process andmay take up to two years to complete
[9]. A number of different factors beyond LV ejection fraction and
size have recently emerged as determinants of the course of DCM.
Together they constitute the pathophysiological basis for the concept
of comprehensive cardiac reverse remodeling and should be systemati-
cally assessed both as possible early measures of therapeutic beneﬁts
and prognostic factors:
• Right ventricular function has a dichotomous role. At diagnosis it
is an important prognostic marker in DCM [11,42]. Interestingly, it
frequently shows a rapid recovery under therapy (up to 6 months).
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namic improvement induced by therapy and precedes LVRR. It is
emerging as an early therapeutic target and an independent prognos-
tic predictor [11]. Improvement in right ventricular function is also
described in CRT implanted patients, probably due to a hemodynamic
improvement very early after resynchronization, and it is associated
with an improvement in survival rates [12]. Conversely, the develop-
ment of right ventricular dysfunction during follow-up is an expres-
sion of structural progression of the disease and portends a negative
outcome [11].
• Functional mitral regurgitation: signiﬁcant mitral regurgitation
maybe considerednot only as a functional bystander but also as an in-
dependent predictor of progressive adverse remodeling [43]. A tight
relation between mitral regurgitation and CRT has been described
[44]. Moderate to severe mitral regurgitation that persists despite
optimal medical treatment or CRT is associated with poorer out-
comes [12,44]. Patients with DCM and persistent severe MR despite
pharmacological therapy should be evaluated for possible invasive
therapeutic strategies such as percutaneous repair of the mitral valve
(i.e. MitraClip®). However, outcome data supporting this therapeutic
intervention in DCM patients is still lacking. Mechanical circulatory
support or even heart transplantation should be also considered
early in these patients.
• Left Bundle Branch Block is a frequent ECGmarker at diagnosis and is
associated with low likelihood of LVRR [9]. Importantly, the develop-
ment of new LBBB during follow-up has emerged as a strong indepen-
dent predictor of major cardiac events [45].
• The onset of atrial ﬁbrillation during follow-up probably represents a
sign of structural progression of the disease and negatively impacts
prognosis [46].
It follows from the above that a multiparametric approach is crucial
in the early management and follow up of DCM under optimal medical
therapy. The clinician should not focus only on left ventricular systolic
function and size but should comprehensively evaluate the behavior
of all heart structures during follow-up (Fig. 1).
4. Gaps of knowledge and future perspectives
Despite an ever-increasing understanding of the pathophysiology of
DCM, prognostic stratiﬁcation of patientswithDCMremains a challenge
for cardiologists, especially in the early phases of the disease. DCMFig. 1. Example of comprehensive reverse remodeling in DCM: note the improvement of LV s
follow-up after 12months of optimal medical therapy. LVEF and right ventricular function als
150 ml/m2; Severe MR; RV-FAC 13%; E/E' 18; LA area 34 cm2; LA volume 125ml. Follow-up (
LA area 23 cm2; LA volume 72 ml. Legend. LVEF: Left Ventricular Ejection Fraction; LVEDD: L
indexed for body surface area; MR: Mitral Regurgitation; RV-FAC: Right Ventricle Fractional Frremains a dynamic disease with a poorly predictable clinical course
and several issues remain unresolved regarding the prospective assess-
ment of the likelihood of reverse remodeling:
– The best timing of evaluation remains debated (Table 2). After re-
moving any possible cause of LV dysfunction, if detectable at diag-
nosis, it is reasonable to evaluate patients 3 to 9 months after
implementation of optimal medical treatment in order to identify
candidates for ICD implant. However, in patients with persistent
severe LV dysfunction, normalization of right ventricular function,
improvement of mitral regurgitation and improvements in dia-
stolic function could portend LVRR. It has been described indeed
that LVRR takes up two years to be completed in response to
medical therapy. Therefore, in these patients, implantation of ICD
might be reasonably delayed. This is especially true in light of the
results of the DANISH trial [47], that did not ﬁnd a survival beneﬁt
in patients with non-ischemic cardiomyopathy who had received
an ICD. Further studies are needed to clarify this issue and to
improve the risk stratiﬁcation of DCM patients in terms of risk of
sudden death.
– Early prediction of LVRR remains amajor knowledge gap in the clin-
ical management of DCM patients. New technologies could improve
our capacity to identify early reverse remodeling. The presence
of late gadolinium enhancement at CMR has been demonstrated as
associated with low probability of LVRR in DCM [48]. However
there is not a deﬁnite agreement in the literature in regards
to CMR late gadolinium enhancement as a predictor of LVRR [49].
Future large studies are needed to conﬁrm the role of CMR in
the early prognostication of DCMs, particularly to assess its ability
to prospectively differentiate responders to therapy from non-
responders. The ability to efﬁciently differentiate early responders
from non-responders would pave the way to studies aimed at un-
derstanding weather these two group of patients warrant different
management strategies (i.e. early device therapy or early insertion
in transplant list) in order to improve outcomes.
– There is very little data regarding the management and risk stratiﬁ-
cation of patientswith normalized ejection fraction. Recently Adamo
et al. found that in patients with a recovered LVEF, a persistent
abnormal echocardiographic global longitudinal strain predicted
the likelihood of having a decreased LVEF during follow-up [21].
However, these authors studied a single retrospective cohort and
further validation of their ﬁndings is pending.hape/dimension and the improvement in MR severity between baseline (left panel) and
o signiﬁcantly improved at follow-up. Basal (left side): LVEF 16%; LVEDD 81mm; LVEDVi
right side): LVEF 56%; LVEDD 55mm; LVEDVi 58ml/m2; Mild MR; RV-FAC 48%; E/E' 6,1
eft Ventricular End Diastolic Dimension; LVEDVi: Left Ventricular End Diastolic Volume
actional Area Change; LA: Left Atrium.
Table 2
The main steps of reverse remodeling evaluation throughout the natural history of DCM.
Time to evaluation Diagnostic work-upa
Baseline – Exclude secondary forms of DCM
• Tachycardiomyopathy
• Substance abuse
• Cardiotoxic agents
• Systemic autoimmune disease
• Peripartum cardiomyopathy
• Endocrine diseases
• Active myocarditis
• DCMs secondary to hypertension
– Obtain genetic data (in presence of familial forms
or presence of red-ﬂags)
– ECG features (LBBB)
3–6 months – Right ventricular recovery
– MR quantiﬁcation
– Left atrial size
– Onset of atrial ﬁbrillation
– Diastolic impairment evaluation
12–24 months – Assess LV function to detect LV Reverse Remodeling
DCM:DilatedCardiomyopathy; LBBB: Left Bundle Branch Block;MR:Mitral Regurgitation;
LV: Left Ventricular; RV: Right Ventricular.
a Need of large future studies to conﬁrm the role of LGE in identifying the possible re-
verse remodeling in response to the therapy.
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speckle tracking, morphological and functional cardiac magnetic reso-
nance including quantiﬁcation of late gadolinium enhancement, mea-
surement of natriuretic peptides, and genetic characterization) are
needed in order to build reliable multiparametric scores that could
encompass the information discussed here and simplify the bedside
risk stratiﬁcation of patients with DCM.
In the near future, extensive genetic characterization of patients
with DCM will probably improve our understanding of DCM. Further-
more, pharmacogenomics is poised to empower the implementation
of pharmacologic treatments optimized for each and every patient.
Finally, the rapidly increasing knowledge of the dynamic interaction
between genetic determinants and environmental factors will likely
bring about better tools to predict the clinical course of DCM.
5. Conclusions
Reverse remodeling is themainmeasure of therapeutic effectiveness
and one of the most important prognostic tools in the management of
patients with DCM. An integrated approach to the evaluation of DCM
patients, including a deeper etiological classiﬁcation and a comprehen-
sive evaluation of cardiac remodeling beyond the left ventricle, is essen-
tial to properly risk stratify and treat this patient population. New
technologies such as echocardiographic speckle tracking, cardiac mag-
netic resonance and genetic testing are progressively improving the
clinician's ability to predict the probability of reverse remodeling and
of its persistence.
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